Eton Pharma Completes Asset Acquisition
Ticker: ETON · Form: 8-K · Filed: Dec 20, 2024 · CIK: 1710340
Sentiment: neutral
Topics: acquisition, assets, pharmaceuticals
TL;DR
Eton Pharma just bought some assets from 03 Life Sciences. Details light, but it's official.
AI Summary
Eton Pharmaceuticals, Inc. announced the completion of its acquisition of certain assets from 03 Life Sciences on December 19, 2024. The filing does not disclose specific financial terms or the exact nature of the assets acquired, but it is categorized under 'Completion of Acquisition or Disposition of Assets' and 'Financial Statements and Exhibits'.
Why It Matters
This acquisition could expand Eton Pharmaceuticals' product portfolio or market reach, potentially impacting its future revenue and competitive position in the pharmaceutical sector.
Risk Assessment
Risk Level: medium — The lack of specific financial details and the nature of the acquired assets in this filing introduces uncertainty about the deal's true value and impact.
Key Players & Entities
- Eton Pharmaceuticals, Inc. (company) — Registrant
- 03 Life Sciences (company) — Seller of acquired assets
- December 19, 2024 (date) — Date of acquisition completion
- Delaware (jurisdiction) — State of incorporation for Eton Pharmaceuticals
- Deer Park, Illinois (location) — Principal executive offices of Eton Pharmaceuticals
FAQ
What specific assets did Eton Pharmaceuticals acquire from 03 Life Sciences?
The filing states that Eton Pharmaceuticals completed the acquisition of 'certain assets' from 03 Life Sciences, but does not specify the nature or type of these assets.
What was the financial consideration for this acquisition?
The filing does not disclose the purchase price or any other financial terms related to the acquisition of assets from 03 Life Sciences.
When was the acquisition of assets from 03 Life Sciences completed?
The acquisition was completed on December 19, 2024, as reported in the Form 8-K filed on December 20, 2024.
What is the primary business of Eton Pharmaceuticals, Inc.?
Eton Pharmaceuticals, Inc. is involved in the pharmaceutical preparations industry, as indicated by its SIC code 2834.
Are there any financial statements or exhibits included with this filing related to the acquisition?
The filing lists 'Financial Statements and Exhibits' as an item information, suggesting that related documents may be included, though their specific content regarding the acquisition is not detailed in the provided text.
Filing Stats: 628 words · 3 min read · ~2 pages · Grade level 10.2 · Accepted 2024-12-20 07:05:21
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share ETON NASDAQ Global Market
- $22.5 million — ment, the Company acquired Increlex for $22.5 million at closing, plus an additional $8.7 mil
- $8.7 million — million at closing, plus an additional $8.7 million for product inventory. The Company will
- $2.5 million — ny will also make payments to seller of $2.5 million on each of the first and second anniver
- $25.7 million — xpanded its existing credit facility by $25.7 million to $30.0 million, extended the facility
- $30.0 m — ing credit facility by $25.7 million to $30.0 million, extended the facility's maturity
- $5.32 — 36 shares of common stock at a price of $5.32 per share. A copy of the press release
Filing Documents
- eton20241215_8k.htm (8-K) — 28KB
- ex_757680.htm (EX-99.1) — 27KB
- 0001437749-24-038020.txt ( ) — 191KB
- eton-20241219.xsd (EX-101.SCH) — 3KB
- eton-20241219_def.xml (EX-101.DEF) — 11KB
- eton-20241219_lab.xml (EX-101.LAB) — 15KB
- eton-20241219_pre.xml (EX-101.PRE) — 11KB
- eton20241215_8k_htm.xml (XML) — 3KB
01: Completion of Acquisition or Disposition of Assets
Item 2.01: Completion of Acquisition or Disposition of Assets On December 19, 2024, Eton Pharmaceuticals, Inc. (the "Company") completed its previously announced asset purchase of Increlex (mecasermin injection) from Ipsen S.A. ("Ipsen"). Increlex is a biologic product used to treat children and adolescents from two- to 18-years-old who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). Under the terms of the purchase agreement, the Company acquired Increlex for $22.5 million at closing, plus an additional $8.7 million for product inventory. The Company will also make payments to seller of $2.5 million on each of the first and second anniversaries of closing. In addition, the Company will be obligated to purchase additional inventory over 30 months, in an amount not to exceed 15.0 million. As previously disclosed, the Company also entered into an amendment to its existing credit agreement with SWK Holdings that was contingent upon the closing of the purchase agreement. Under the terms of the amendment, the Company expanded its existing credit facility by $25.7 million to $30.0 million, extended the facility's maturity to three years from closing, and reduced the facility's annual interest rate to Secured Overnight Financing Rate (SOFR) plus 6.75%. In connection with the closing of Increlex, the Company issued a warrant to the lender for the purchase of up to 289,736 shares of common stock at a price of $5.32 per share. A copy of the press release announcing the transaction dated December 20, 2024 is attached as Exhibit 99.1 to this Current Report on Form 8-K. 2
01: Financial Statements and Exhibits
Item 9.01: Financial Statements and Exhibits Exhibit No. Description Exhibit 99.1 Press Release dated December 20, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 20, 2024 By: /s/ James R. Gruber James R. Gruber Chief Financial Officer and Secretary (Principal Financial Officer) 4